Dr. Falchi’s areas of interest include non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma. His current research is focused on the use of immunotherapy for the treatment of patients with B-cell NHL through the conduct of clinical and translational studies. He is the lead investigator in multiple national and global immunotherapy trials for patients with B-cell NHL. He authored or co-authored over 60 articles published in peer-reviewed journals, as well as numerous abstracts and several book chapters. His work has received extensive coverage by media outlets, including The New York Times Magazine, Thomson Reuters and other press agencies. Dr. Falchi is Co-Editor-In-Chief of Oncoimmunology, Associate Editor for Frontiers in Oncology, and member of the Editorial Board for Blood Advances and serves as an ad-hoc or recurrent peer-reviewer for numerous high-profile journals, such as Blood and JAMA Oncology. He is recipient of several awards including the 2022-2025 Lymphoma Research Foundation Career Development Award, and 2022 Memorial Sloan-Kettering Steven A. Greenberg Lymphoma Research Award.